Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE vs METHERGINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Methylergonovine is an ergot alkaloid that acts as a partial agonist at α-adrenergic receptors in the uterine smooth muscle, causing sustained contractions. It also exhibits serotonergic (5-HT2) and dopaminergic activity.
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Prevention and treatment of postpartum hemorrhage due to uterine atony,Management of incomplete abortion
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
0.2 mg intramuscularly or intravenously after delivery of placenta and every 2-4 hours as needed, up to a maximum of 5 doses.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Terminal elimination half-life is approximately 2–3 hours in healthy adults; prolonged in hepatic impairment.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily hepatic via CYP3A4 with significant first-pass metabolism; active metabolite is methylergonovine itself; excreted mainly in bile and urine.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Biliary/fecal excretion accounts for ~80% of metabolites.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Approximately 93% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
0.6 L/kg (range 0.3–0.8 L/kg), indicating moderate distribution into tissues.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Oral bioavailability is approximately 10–20% due to extensive first-pass metabolism. Intramuscular administration provides 100% bioavailability.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific dose adjustment recommended; use with caution in renal impairment due to risk of hypertension.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B, use with caution and monitor for signs of toxicity.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Not recommended for pediatric use; safety and efficacy in children have not been established.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Use with caution in elderly patients due to increased sensitivity to vasoconstrictive effects and higher risk of hypertension and myocardial ischemia.
None.
Not for use during pregnancy (except during delivery) due to risk of uterine tetany and fetal hypoxia. Contraindicated in patients with hypertension, preeclampsia, or eclampsia due to risk of severe hypertension and stroke.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Risk of severe hypertension, especially in patients with preeclampsia, eclampsia, or hypertension.,Use with caution in patients with sepsis, hepatic or renal impairment, or coronary artery disease.,May cause ergotism with prolonged use or high doses (symptoms: vasospasm, ischemia).,Monitor blood pressure and uterine response during administration.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Hypersensitivity to ergot alkaloids,Pregnancy (for antepartum use),Hypertension, preeclampsia, or eclampsia,Peripheral vascular disease,Coronary artery disease,Severe hepatic or renal impairment,Sepsis
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Avoid grapefruit juice as it may increase serum levels of methylergonovine via CYP3A4 inhibition. No specific food restrictions other than avoiding excessive caffeine intake, which may potentiate vasoconstrictive effects.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Methergine (methylergonovine) is contraindicated in pregnancy due to its oxytocic properties and risk of uterine hyperstimulation, fetal distress, and abortion. First trimester: potential teratogenic effects not well studied; avoid use. Second and third trimesters: can cause abruptio placentae, premature labor, and fetal anoxia. It is FDA Pregnancy Category X.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Methylergonovine is excreted into breast milk in small amounts; the milk-to-plasma ratio is approximately 1.0. Adverse effects in nursing infants are rare but may include diarrhea, vomiting, and hypertension. It is generally considered compatible with breastfeeding when used short-term for postpartum hemorrhage. Avoid prolonged use.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Not applicable; the drug is contraindicated during pregnancy. No dose adjustments are recommended for use during pregnancy as it should not be used.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
METHERGINE (methylergonovine) is an ergot alkaloid used primarily for postpartum hemorrhage due to uterine atony. Do not use for routine induction of labor or for threatened abortion. Avoid in patients with hypertension, preeclampsia, coronary artery disease, or severe hepatic/renal disease. Monitor blood pressure closely during administration. Administer intramuscularly for rapid effect; onset is 2-5 minutes. Intravenous administration should be reserved for emergencies due to risk of hypertensive crisis. Contraindicated in pregnancy except immediately after delivery. Drug interactions: avoid concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, macrolides, protease inhibitors) due to risk of ergotism and vasospasm. As of April 2025, there is no generic form; brand METHERGINE only.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
This medication is used to prevent or treat excessive bleeding after childbirth by causing contractions of the uterus.,Report immediately if you experience severe headache, chest pain, vision changes, muscle cramps, or numbness/tingling in the arms or legs.,Avoid breastfeeding within 8 hours after the last dose if possible; if breastfeeding is necessary, pump and discard for 8 hours to reduce infant exposure.,Do not use this medication if you have uncontrolled high blood pressure, heart disease, or liver/kidney disease.,Avoid alcohol and grapefruit juice while on this medication as they may affect blood levels.,Take this medication exactly as prescribed; do not take double doses if a dose is missed.
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE vs METHERGINE, answered by our medical review team.
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. METHERGINE is a Ergot Alkaloid Uterotonic that works by Methylergonovine is an ergot alkaloid that acts as a partial agonist at α-adrenergic receptors in the uterine smooth muscle, causing sustained contractions. It also exhibits serotonergic (5-HT2) and dopaminergic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE and METHERGINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. The standard adult dose of METHERGINE is: 0.2 mg intramuscularly or intravenously after delivery of placenta and every 2-4 hours as needed, up to a maximum of 5 doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE and METHERGINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. METHERGINE is classified as Category C. Methergine (methylergonovine) is contraindicated in pregnancy due to its oxytocic properties and risk of uterine hyperstimulation, fetal distress, and abortion. First trimester: po. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.